Top

Published in:

01-01-2009 | Original Article

Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients

Authors: Luca Degrate, Cinzia Nobili, Claudio Franciosi, Roberto Caprotti, Fernando Brivio, Fabrizio Romano, Biagio Eugenio Leone, Rosangela Trezzi, Franco Uggeri

Published in: Langenbeck's Archives of Surgery | Issue 1/2009

Abstract

Background and aims

Innate immunity cells play a crucial role in host anticancer defense: cancer patients with high levels of natural killer (NK) cells and eosinophils have a better prognosis. Recombinant interleukin-2 (rIL-2) immunotherapy stimulates innate immunity cells. This study aims to evaluate the toxicity of pre- and postoperative rIL-2 treatment and the effects on innate immunity both in peripheral blood and in cancer tissue of patients with resectable pancreatic adenocarcinoma.

Materials and methods

Seventeen patients received high dose rIL-2 preoperative subcutaneous administration and two low dose postoperative cycles. We evaluated NK cell and eosinophil count in blood and in pancreatic surgical specimens.

Results

Toxicity was moderate. In the early postoperative period, blood NK cells and eosinophils significantly increased compared to basal values (p < 0.02). Histopathological analysis did not find significant intratumoral infiltration of NK cells nor of eosinophils.

Conclusions

Preoperative high dose rIL-2 administration is able to counteract surgery-induced deficiency of NK cells and eosinophils in peripheral blood in the early postoperative period, although it cannot overcome local mechanisms of immune tumor escape in cancer tissue. The amplification of innate immunity, induced by immunotherapy, may improve the control of metastatic cells spreading in the perioperative period.

Cruickshank AH, Benbow EW (1995) Pathology of the pancreas, 2nd edn. Springer, London

Rosewicz S, Wiedenmann B (1997) Pancreatic carcinoma. Lancet 15:786–792

Yeo CJ, Cameron JL (1998) Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 383:129–133PubMed

Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J (2005) Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 390:94–103 doi:10.1007/s00423-004-0476-9 PubMedCrossRef

Fearon DT, Locksley RM (1996) The instructive role of innate immunity in the acquired immune response. Science 272:50–54 doi:10.1126/science.272.5258.50 PubMedCrossRef

Lissoni P, Viviani S, Santoro A (1989) Serum levels of Interleukin-2 in cancer patients: preliminary considerations. Int J Biol Markers 4:203–206PubMed

Maltoni M, Pirovano M, Nanni O, Marinari M, Indelli M, Gramazio A et al (1997) Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 13:1–9 doi:10.1016/S0885-3924(96)00265-5 PubMedCrossRef

von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C et al (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3):925s–932s

Plate JM, Harris JE (2000) Immune cell functions in pancreatic cancer. Crit Rev Immunol 20:375–392PubMed

10.

Pollock RE, Lotzova E, Stanford SD (1991) Mechanism of surgical stress impairment of human perioperative natural killer cell cytotoxicity. Arch Surg 126:338–342PubMed

11.

Constantian MB, Menzoian JO, Nimberg RB, Schmid K, Mannick JA (1977) Association of a circulating immunosuppressive polypeptide with operative and accidental trauma. Ann Surg 185:73–77 doi:10.1097/00000658-197701000-00012 PubMedCrossRef

12.

Lennard TWJ, Shenton BK, Borzotta A, Donnelly PK, White M, Gerrie LM et al (1985) The influence of surgical operations on components of the human immune system. Br J Surg 72:771–776 doi:10.1002/bjs.1800721002 PubMedCrossRef

13.

Griffith CD, Rees RC, Platts A, Jermy A, Peel J, Rogers K (1984) The nature of enhanced natural killer lymphocyte cytotoxicity during anaesthesia and surgery in patients with benign disease and cancer. Ann Surg 200:753–758 doi:10.1097/00000658-198412000-00014 PubMedCrossRef

14.

Akiyoshi T, Koba F, Arinaga S, Miyazaki S, Wada T, Tsuji H (1985) Impaired production of interleukin-2 after surgery. Clin Exp Immunol 59:45–49PubMed

15.

Prochazka M, Vyhnanek F, Jira M, Streicek J (1987) Effect of interleukin-2 on peripheral blood mononuclear cells in severity injured patients. Acta Chir Scand 153:401–404PubMed

16.

Brivio F, Lissoni P, Mancini D, Tisi E, Tancini G, Barni S et al (1991) Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. Am J Surg 161:466–469 doi:10.1016/0002-9610(91)91113-W PubMedCrossRef

17.

Hamid J, Bancewicz J, Brown R, Ward C, Irving MH, Ford WL (1984) The significance of changes in blood lymphocyte populations following surgical operations. Clin Exp Immunol 56:49–57PubMed

18.

Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L (1996) Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology 53:263–268PubMed

19.

Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169–1176 doi:10.1126/science.3131876 PubMedCrossRef

20.

Brivio F, Lissoni P, Perego MS, Dissoni A, Fumagalli L (2001) Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications. J Biol Regul Homeost Agents 15:370–374PubMed

21.

Jeal W, Goa K (1997) Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. BioDrugs 7:285–317PubMed

22.

Angevin E, Valteau-Couanet D, Farace F, Dietrich PY, Lecesne A, Triebel F et al (1995) Phase I study prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 18:188–195PubMed

23.

Lindemann A, Brossart P, Hoffken K, Flasshove M, Voliotis D, Diehl V et al (1993) Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother 37:307–315 doi:10.1007/BF01518453 PubMedCrossRef

24.

Nicolini A, Mancini PA, Ferrari P, Anselmi L, Sagripanti A, Carpi A (1996) Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients. Biomed Pharmacother 50:344–349 doi:10.1016/S0753-3322(96)89666-1 PubMedCrossRef

25.

Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L et al (1996) Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 2:669–677PubMed

26.

Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G et al (1992) Effects of a preoperative therapy with IL-2 on surgery induced lymphocytopenia in cancer patients. Oncology 49:215–218PubMedCrossRef

27.

Deehan DJ, Heys SD, Ashby J, Eremin O (1995) Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol 21:16–22 doi:10.1016/S0748-7983(05)80061-7 PubMedCrossRef

28.

Nieken J, Sleijfer DT, Buter J, de Leij L, Mulder NH (1996) Outpatient based subcutaneous interleukin-2 momotherapy in advanced renal cell carcinoma: an update. Cancer Biother Radiopharm 11:289–295PubMed

29.

Guida M, Abbate I, Casamassima A, Musci MD, Latorre A, Lorusso V et al (1995) Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications. Cancer Biother 10:195–203PubMed

30.

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214 doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 PubMedCrossRef

31.

Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 97:2731–2736 doi:10.1073/pnas.050588297 PubMedCrossRef

32.

Pross HF, Lotzova E (1993) Role of natural killer cells in cancer. Nat Immunol 12:279–292

33.

Lechin F, Van Der Djis B (2004) Natural killer cells activity and neuroimmunological treatment of cancer. Clin Cancer Res 10:8120–8121 doi:10.1158/1078-0432.CCR-04-1508 PubMedCrossRef

34.

Wong DTW, Bowen SM, Elovic A, Gallagher GT, Weller PF (1999) Eosinophil ablation and tumor development. Oral Oncol 35:496–501 doi:10.1016/S1368-8375(99)00023-8 PubMedCrossRef

35.

Wallace ME, Smyth MJ (2005) The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity. Springer Semin Immunopathol 27:49–64 doi:10.1007/s00281-004-0195-x PubMedCrossRef

36.

Rosenberg SA (2001) Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 250:462–475 doi:10.1046/j.1365-2796.2001.00911.x PubMedCrossRef

37.

Cerea K, Romano F, Ferrari Bravo A, Motta V, Uggeri F, Brivio F et al (2001) Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients. J Surg Oncol 78:32–37 doi:10.1002/jso.1120 PubMedCrossRef

38.

Nichols P, Ramsden CW, Ward U, Sedman PC, Primrose JN (1992) Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 52:5765–5769PubMed

39.

Miller JS (2001) The biology of natural killer cells in cancer, infection and pregnancy. Exp Hematol 29:1157–1168 doi:10.1016/S0301-472X(01)00696-8 PubMedCrossRef

40.

Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K et al (1993) In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin-2. Role of interleukin 5. Int J Cancer 54(5):887 doi:10.1002/ijc.2910540528 CrossRef

41.

Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA (1998) Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 46:318–326 doi:10.1007/s002620050493 PubMedCrossRef

42.

Fehniger TA, Bluman EM, Porter MM, Mrozer E, Cooper MA, Van Deusen JB et al (2000) Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 106:117–124 doi:10.1172/JCI6218 PubMedCrossRef

43.

Lissoni P (1997) Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J Sci Am 3(suppl 1):S115–S120PubMed

44.

Brittenden J, Heys SD, Ross J, Eremin O (1996) Natural killer cells and cancer. Cancer 77:1226–1243 doi:10.1002/(SICI)1097-0142(19960401)77:7<1226::AID-CNCR2>3.0.CO;2-G PubMedCrossRef

45.

Davey RT, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE et al (1997) Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 175:781–789PubMedCrossRef

46.

Uhr JW, Scheuermann RH, Street NE, Vitetta ES (1997) Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 3:505–509 doi:10.1038/nm0597-505 PubMedCrossRef

47.

Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D et al (2001) Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 92:2286–2296 doi:10.1002/1097-0142(20011101)92:9<2286::AID-CNCR1575>3.0.CO;2-I PubMedCrossRef

48.

Bovo G, Brivio F, Brenna A, Fumagalli L, Perego P, Brivio O et al (1995) Pre-operative Interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma. Pathologica 87(2):135–138PubMed

49.

Iwasaki K, Torisu M, Fujimura T (1986) Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer 58:1321–1327 doi:10.1002/1097-0142(19860915)58:6<1321::AID-CNCR2820580623>3.0.CO;2-O PubMedCrossRef

50.

Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88:1544–1548 doi:10.1002/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-S PubMedCrossRef

51.

Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ et al (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect—a histopathological and immunohistochemical study. BMC Cancer 1(1):7 doi:10.1186/1471-2407-1-7 PubMedCrossRef

52.

Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H et al (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88:577–583 doi:10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V PubMedCrossRef

53.

Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F (1999) Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 189:487–495 doi:10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I PubMedCrossRef

Title: Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients
Authors: Luca Degrate
Cinzia Nobili
Claudio Franciosi
Roberto Caprotti
Fernando Brivio
Fabrizio Romano
Biagio Eugenio Leone
Rosangela Trezzi
Franco Uggeri
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 1/2009
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-008-0393-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients

Abstract

Background and aims

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Probiotics and acute pancreatitis need a long way to go

Reply to the letter by M. Tez regarding our article “Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance”

Effect of surgical work volume on postoperative complication: superiority of specialized center in gastric cancer treatment

Tension pneumothorax, pneumoretroperitoneum, and subcutaneous emphysema after colonoscopic polypectomy: a case report and review of the literature

Long-term comorbidity of diabetes mellitus is a risk factor for perineal wound complications after an abdominoperineal resection

Palliative operation for the treatment of alveolar echinococcosis